Pharmaxis Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
34,182.00
54,138.00
39,209.00
21,504.00
31,073.00
Total Accounts Receivable
4,518.00
5,735.00
4,849.00
4,435.00
2,394.00
Inventories
2,150.00
1,575.00
2,213.00
2,570.00
2,398.00
Other Current Assets
45.00
92.00
146.00
134.00
119.00
Total Current Assets
40,895.00
61,540.00
46,417.00
28,643.00
35,984.00
Net Property, Plant & Equipment
22,448.00
19,634.00
17,793.00
14,860.00
12,451.00
Total Investments and Advances
-
-
1,297.00
1,309.00
1,090.00
Long-Term Note Receivable
2,146.00
1,021.00
-
-
-
Intangible Assets
1,258.00
363.00
146.00
503.00
446.00
Other Assets
-
-
-
119.00
126.00
Total Assets
66,747.00
82,558.00
65,653.00
45,434.00
50,097.00
ST Debt & Current Portion LT Debt
1,458.00
1,603.00
864.00
981.00
1,098.00
Accounts Payable
1,776.00
2,700.00
2,196.00
3,324.00
2,130.00
Income Tax Payable
126.00
16.00
-
-
-
Other Current Liabilities
4,922.00
3,829.00
7,952.00
6,216.00
5,016.00
Total Current Liabilities
8,282.00
8,148.00
11,012.00
10,521.00
8,244.00
Long-Term Debt
37,980.00
34,955.00
9,258.00
8,270.00
7,171.00
Provision for Risks & Charges
323.00
278.00
267.00
260.00
166.00
Other Liabilities
2,095.00
2,856.00
24,190.00
22,862.00
23,398.00
Total Liabilities
48,680.00
46,237.00
44,727.00
41,913.00
38,979.00
Common Equity (Total)
18,067.00
36,321.00
20,926.00
3,521.00
11,118.00
Total Shareholders' Equity
18,067.00
36,321.00
20,926.00
3,521.00
11,118.00
Total Equity
18,067.00
36,321.00
20,926.00
3,521.00
11,118.00
Liabilities & Shareholders' Equity
66,747.00
82,558.00
65,653.00
45,434.00
50,097.00

About Pharmaxis

View Profile
Address
20 Rodborough Road
Sydney New South Wales (NSW) 2086
Australia
Employees -
Website http://www.pharmaxis.com.au
Updated 07/08/2019
Pharmaxis Ltd. operates as a specialty pharmaceutical company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. It operates through the following segments: Bronchitol and Aridol Business and New Drug Development. The Bronchitol and Aridol Business segment covers the ongoing clinical development, manufacture, and sale of the Bronchitol and Aridol globally.